|
||||||
|
THE CURRENT TIME at LC Labs is: |
|||||
[Sorafenib Tosylate] [Bay 43-9006] [Nexavar]
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
100 mg |
98 |
81 |
54 |
11800 |
| ||
|
300 mg |
225 |
187 |
124 |
27000 |
| ||
|
1 g |
465 |
386 |
256 |
55800 |
| ||
| Compare Quality and Prices LC Labs vs. Other Suppliers | |||
|---|---|---|---|
| US Dollars ($) | European Union Euros (€) | British Pounds (£) | Japanese Yen (¥) |
M.W. 637.04
C21H16ClF3N4O3C7H8O3S
[475207-59-1]
M.I. 14: 8720
Storage: Store at or below -20 ºC. Solubility: Very soluble in DMSO, up to about 200 mg/mL; very poorly soluble in water or ethanol. Disposal: A
View the MSDS for this product
Sorafenib (Bay 43-9006) is a novel bi-aryl urea compound that inhibits cell proliferation by targeting the ERK pathway and angiogenesis by targeting the receptor tyrosine kinases VEGFR-2 and PDGFR-β and their associated signaling cascades. Although sorafenib was initially developed as a Raf kinase inhibitor (IC50 = 6 nM), it has since been shown to have activity against many receptor tyrosine kinases involved in tumorigenesis and angiogenesis including FGFR-1, wt BRAF and V599E mutant BRAF, as well as members of the so-called "split kinase" family: VEGFR-2, VEGFR-3, PDGFR-β, c-KIT, and Flt3. However, sorafenib is not active against erbB1, erbB2, ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-MET, c-yes, PKB, PKA, cdk1/cyclinB, PKC, and pim-1. In cellular mechanistic assays, sorafenib decreased basal phosphorylation of the ERK pathway in melanoma, breast, colon, and pancreatic tumor cell lines. Wilhelm, S.M., et al. "BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis." Cancer Res. 64: 7099-7109 (2004).
Biochemical Assay * |
IC50 (nM) ± SD |